Navigation Links
The Lancet Publishes Data from Protege, MacroGenics' Phase 3 Clinical Study of Teplizumab in Type 1 Diabetes Patients
Date:6/28/2011

ased on three core technology platforms, which include: (1) a method for generating cancer stem-like cells; (2) Dual-Affinity Re-Targeting (or DART) technology, which allows the company to incorporate multiple specificities within a single recombinant molecule; and (3) Fc optimization, which enhances antibody-dependent effector functions. The company has global product development collaborations with Boehringer Ingelheim and Pfizer Inc.  For more information about MacroGenics, please visit www.macrogenics.com.

Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company's ability to raise additional capital, and risks related to the Company's ability to initiate, and enroll patients in, planned clinical trials. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by law.  

(1)Sherry N, Hagopian W, Ludvigsson J, et al.  Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomized, placebo-controlled trial.  www.thelancet.com. Published online June 28, 2011; DOI:10.1016/S0140-6736(11)60931-8.


'/>"/>
SOURCE MacroGenics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Final Published Trial Data in The Lancet Supports Safety and Effectiveness of MicroVention-Terumos HydroCoil® Embolic System for Treatment of Cerebral Aneurysms
2. QNEXA® Phase 3 Data in The Lancet Show Significant Weight Loss and Broad Improvements in Co-Morbidities
3. Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer
4. CHAMPION Study Published in The Lancet
5. Phase III Data Published in Lancet Show Novartis Drug Zometa® Improves Overall Survival in Newly Diagnosed Multiple Myeloma Patients
6. Phase III Data Showing Improved Survival With Jevtana® (cabazitaxel) Injection in Second-Line Advanced Prostate Cancer Published in The Lancet
7. Data Published in The Lancet Compare Dabigatran Etexilate to Dose-Adjusted Warfarin Across RE-LY® Trial Centers
8. Orexigen® Therapeutics Announces Publication of COR-I Phase 3 Study of Contrave in Lancet
9. Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010
10. The Lancet publishes new data demonstrating superior efficacy of Victoza(R) (liraglutide [rDNA] injection) compared to Januvia(R) (sitagliptin) in the treatment of type 2 diabetes
11. Landmark Study in The Lancet Oncology Shows Capecitabine (Xeloda(R)) Combination Therapy Reduces Early Breast Cancer Recurrence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... , Deutschland, October 19, 2014 ... gefragt. Das Problem dabei ist, dass ... mit der Kompetenz zu teilen. Es ... deshalb freuen wir uns umso mehr, dass es ... ihre Gepflogenheiten bei Kühlketten aufzuschreiben - mit einem ...
(Date:10/17/2014)... THOUSAND OAKS, Calif. , Oct. 17, 2014 /PRNewswire/ ... appointment of R. Sanders Williams , M.D., president ... L. Mahley Distinguished Professor.  "We are ... the Amgen Board," said Robert A. Bradway , ... deep and distinguished experience in academic medicine and his ...
(Date:10/17/2014)... 2014 ... has announced the addition of the  ... Automated External Defibrillators (AED) Market"  report ... ,The report North American Automated External ... of devices based upon following sub-segments ...
Breaking Medicine Technology:Vergleichsbericht zu Pharma-Kühlketten und CRT 2Amgen Announces Appointment Of R. Sanders Williams To Board Of Directors 2Amgen Announces Appointment Of R. Sanders Williams To Board Of Directors 3Micro Market Monitor : North American Automated External Defibrillators (AED) Market 2
... Symmetry Medical Inc. (NYSE: SMA ), a leading ... and other medical markets, announced today that it will release ... 3, 2009 before the market opens on Thursday, November 5, ... 8:00 a.m. ET on Thursday, November 5, 2009. , ...
... Ikaria Holdings, Inc. today announced that it has been ... by the New Jersey Business & Industry Association (NJBIA), ... Ikaria earned the award based on criteria including ... creation of new jobs. , "We are delighted that ...
Cached Medicine Technology:Symmetry Medical to Report Third Quarter 2009 Financial Results on November 5, 2009 2Ikaria Receives Award for Excellence by New Jersey Business & Industry Association 2
(Date:10/20/2014)... It’s hard to imagine what it’s like to live without ... world, it’s a reality. And while new shoes are considered ... walk barefoot on rocky terrain or sewage-lined streets just to ... , Buckner International's Shoes for Orphan Souls ... to encourage support for Air1 and while also providing new ...
(Date:10/19/2014)... 20, 2014 Hastings and Hastings, a ... of service throughout the greater Phoenix area and across ... with regard to catastrophic automobile accidents. Statistics have indicated ... and throughout Arizona. As such, Hastings and Hastings has ... representation for those who have been injured through no ...
(Date:10/19/2014)... Texas (PRWEB) October 20, 2014 ... development for Partial Seizure, complete with comparative analysis ... mechanism of action (MoA), route of administration (RoA) ... featured news and press releases. It also reviews ... Partial Seizure and special features on late-stage and ...
(Date:10/19/2014)... SweetDressy.com, a professional company of women’s ... for long evening dresses . All the company’s ... the current discount is up to 66 percent off. ... in the fashion field. Its dress specialists are striving ... various parts of the world. All the company’s items ...
(Date:10/19/2014)... that causes inflammation in the spinal joints and ... ancient Egyptian royal families. Now a new study ... journal of the American College of Rheumatology (ACR), ... condition called diffuse idiopathic skeletal hyperostosis (DISH) in ... 20th Dynasties. , Ankylosing spondylitis is a ...
Breaking Medicine News(10 mins):Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 2Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4Health News:Promotion For Beautiful Long Evening Dresses Launched By SweetDressy.com 2Health News:Mummy remains refute antiquity of ankylosing spondylitis 2
... March 17 CUREXO Technology Corporation, pioneer in ... products for orthopaedic applications, which is focused on ... they received the NSAI (National Standards of Ireland) ... I.S. EN ISO 13485:2003.CUREXO Technology Company has been ...
... 17 FRIED LICE: "You don,t have to be such a ... manufacturing company, is set to introduce the latest in delousing technology. ... Disease Control "CDC" website. The guidelines are clear in stating: "to ... of 130 degrees." Lice Safe was able to adapt a ...
... finds, , , TUESDAY, March 17 (HealthDay News) -- ... that black male children may have a greater risk ... survey included 8,203 people, from infants to seniors who ... issues with eggs, milk, peanuts and shrimp. The ...
... awarded a project to provide interactive, high-quality medical video for 28 ... will be demonstrating the solutions being implemented at WFUBMC at the ... West Building, Chicago, Illinois. Rivulet is in Booth #2428. , ... ...
... - New $2.1 Million SBIR Grant Extends NHGRI ... Whole Genome Imaging and Analysis Platform -PHILADELPHIA, March ... nanoscale platforms for biomedical research, molecular diagnostics and ... II grant from the National Human Genome Research ...
... Germgard Lighting LLC, a New Jersey-based, early-phase ... revolutionary, ultra-fast, bare-hand sanitation capability. Germgard,s technology will ... by curtailing infections resulting from stays in hospitals.Hospital ... their families, and undermines the financial well-being of ...
Cached Medicine News:Health News:CUREXO Technology Corporation Receives Quality Certificate 2Health News:Lice Safe Introduces Licen Tool 2Health News:Wake Forest Baptist and Rivulet Connect New Operating Rooms with Interactive Video 2Health News:Wake Forest Baptist and Rivulet Connect New Operating Rooms with Interactive Video 3Health News:BioNanomatrix Awarded Phase II NIH Grant to Support Development of Its Single-Molecule Nanoscale Whole Genome Analyzer 2Health News:Disruptive Hand Sanitation Product to Save Healthcare Industry Billions 2
... Para 5X is a whole blood hematology ... 60C+, 80 and 120, and the Coulter ... offers a unique white cell differential, positioning ... algorithms on the systems. The product offers ...
... blood assayed hematology control, offers complete assay ... available with the Coulter GENS, STKS, MAXM ... open-vial stability, 105-day closed-vial stability and is ... The 4.0ml pierceable cap vial is compatible ...
Abiomed introduces its new intra-aortic balloon (IAB); an easy-to-insert, minimally invasive technology designed to enhance blood flow to the heart and other organs for patients with diminished heart...
Diagnosoft HARP is designed for rapid analysis of tagged cardiac MR images using the HARP technology, which is packaged into an intuitive, easy-to-use graphic user interface....
Medicine Products: